# US 2020/0261518 A1 · Methods and compositions relating to microbial treatment and diagnosis of disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0261518 A1
- Document ID: US20200261518A1
- Status: Published application
- Kind: A1
- Application number: 16/830,995
- Filed: 2020-03-26
- Published: 2020-08-20
- Earliest claimed: 2014-10-31
- Assignees: Pendulum Therapeutics, Inc.
- Applicants: Pendulum Therapeutics, Inc.
- Inventors: Colleen CUTCLIFFE; John S. EID; James H. BULLARD; Marcus F. SCHICKLBERGER
- Web page: https://patentgrep.com/patent/US20200261518A1

## CPC

- A61K 35/745: Bifidobacteria
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2846: {Poly(meth)acrylates}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 9/4816: {Wall or shell material}
- A61K 9/4891: {Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004)}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/733: Fructosans, e.g. inulin
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C12N 1/20: Bacteria; Culture media therefor
- C12Q 1/689: for bacteria
- G01N 33/66: involving blood sugars, e.g. galactose
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K 2035/115: {Probiotics}
- G01N 2333/605: Glucagons
- G01N 2800/04: Endocrine or metabolic disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.

## Claims

### Claim 1

An oral dosage form comprising an isolated and purified microbe comprising a 16S rRNA sequence comprising at least 97% sequence identity to a 16S rRNA sequence of Eubacterium hallii, wherein the oral dosage form is formulated for delivery of the isolated and purified microbe to an ileum region of a gastrointestinal tract, a large intestine region of the gastrointestinal tract, or a combination thereof, wherein the isolated and purified microbe has been grown in a substantially plant-based medium comprising yeast extract, a plant-derived peptone, a plant-derived hydrolysate, or a combination thereof.

### Claim 2 (depends on 1)

The oral dosage form of claim 1, wherein the oral dosage form comprises a carrier or excipient selected from the group consisting of malt, an oil, an oil of petroleum, animal, vegetable or synthetic origin, peanut oil, soybean oil, mineral oil, sesame oil, glycol, propylene glycol, alginate, sodium alginate, a lipid, a granulating agent, and a combination thereof.

### Claim 3 (depends on 1)

The oral dosage form of claim 1, wherein the oral dosage from comprises an antioxidant, a vitamin, ascorbic acid, a lipid, a mineral, or a combination thereof.

### Claim 4 (depends on 1)

The oral dosage form of claim 1, further comprising a prebiotic.

### Claim 5 (depends on 4)

The oral dosage form of claim 4, wherein the prebiotic comprises dietary fiber, starch, wheat bran, biotin, or a combination thereof.

### Claim 6 (depends on 1)

The oral dosage form of claim 1, wherein the oral dosage form comprises at least one preservative.

### Claim 7 (depends on 1)

The oral dosage form of claim 1, wherein the oral dosage form is substantially free of preservatives.

### Claim 8 (depends on 1)

The oral dosage form of claim 1, wherein the isolated and purified microbe is encapsulated within a suitable vehicle.

### Claim 9 (depends on 1)

The oral dosage form of claim 1, wherein the isolated and purified microbe is encapsulated in a liposome, microsphere, or microparticle.

### Claim 10 (depends on 1)

The oral dosage form of claim 1, wherein the isolated and purified microbe is encapsulated in a suitable vehicle for sustained release.

### Claim 11 (depends on 1)

The oral dosage form of claim 1, wherein the oral dosage form is a liquid that comprises glycerol.

### Claim 12 (depends on 1)

The oral dosage form of claim 1, wherein the substantially plant-based medium is a medium that lacks animal-derived components.

### Claim 13 (depends on 12)

The oral dosage form of claim 12, wherein the medium that lacks animal-derived components comprises an added vitamin or trace mineral.

### Claim 14 (depends on 13)

The oral dosage form of claim 13, wherein the added vitamin or trace mineral comprises biotin, calcium, calcium pantothenate, myoinositol, p-aminobenzoic acid, pyridoxine hydrochloride, riboflavin, thiamine, vitamin B12, nicotinic acid, cobalt, copper, iron, magnesium, manganese, molybdenum, nickel, selenium, zinc, potassium, or a combination thereof.

### Claim 15 (depends on 12)

The oral dosage form of claim 12, wherein the medium that lacks animal-derived components comprises cysteine.

### Claim 16 (depends on 1)

The oral dosage form of claim 1, wherein the oral dosage form is in a granule form.

### Claim 17 (depends on 1)

The oral dosage form of claim 1, wherein the isolated and purified microbe is lyophilized, wherein the oral dosage form comprises mannitol, sucrose, or a combination thereof.

### Claim 18 (depends on 1)

The oral dosage form of claim 1, wherein the oral dosage form is administered to a subject in combination with another agent.

### Claim 19 (depends on 18)

The oral dosage form of claim 18, wherein the oral dosage form is administered simultaneously with the another agent, prior to administration of the another agent, or subsequent to administration of the another agent.

### Claim 20 (depends on 1)

The oral dosage form of claim 1, wherein the oral dosage form is formulated for administration to a subject 1, 2, 3, or more times daily.

### Claim 21 (depends on 1)

The oral dosage form of claim 1, wherein the oral dosage form is capable of increasing butyrate production in a subject.

### Claim 22 (depends on 1)

The oral dosage form of claim 1, wherein the oral dosage form is capable of altering GLP-1 production in a subject.

### Claim 23 (depends on 1)

The oral dosage form of claim 1, wherein the oral dosage form is capable of altering GPCR signaling in a subject.

### Claim 24 (depends on 1)

The oral dosage form of claim 1, wherein the isolated and purified microbe is capable of converting intermediate molecules into butyrate in a subject.

### Claim 25 (depends on 24)

The oral dosage form of claim 24, wherein the intermediate molecules comprise lactate, acetate, or a combination thereof.

### Claim 26 (depends on 1)

The oral dosage form of claim 1, wherein the oral dosage form is capable of increasing glucose control, increasing insulin sensitivity, increasing weight loss, decreasing appetite, or a combination thereof in a subject.

### Claim 27 (depends on 1)

A method of increasing insulin sensitivity, increasing glucose tolerance, treating insulin resistance, treating metabolic syndrome, or treating type 2 diabetes mellitus in a subject in need thereof, comprising administering to the subject the oral dosage form of claim 1.
